All news

Genmab shares double on cancer trial wins

CNBC · RSS · · AI-summarised by FinFlash

Genmab's shares have doubled over three months following a string of successful cancer drug trial results. The Danish biotech is using those wins to strengthen its push to own more of the medicines it develops, rather than licensing them out to larger partners. The rally reflects growing investor confidence in that strategy shift.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.